Xeris Biopharma Holdings Inc logo

Xeris Biopharma Holdings Inc

3
NAS:XERS (USA)   Ordinary Shares
$ 3.04 +0.04 (+1.33%) 04:00 PM EST
At Loss
P/B:
107.14
Market Cap:
$ 414.37M
Enterprise V:
$ 599.64M
Volume:
2.00M
Avg Vol (2M):
2.31M
Also Trade In:
Volume:
2.00M
At Loss
Avg Vol (2M):
2.31M

Business Description

Xeris Biopharma Holdings Inc logo
Xeris Biopharma Holdings Inc
NAICS : 325412 SIC : 2834
ISIN : US98422L1070

Share Class Description:

XERS: Ordinary Shares
Description
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.
Name Current Vs Industry Vs History
Cash-To-Debt 0.29
Equity-to-Asset 0.01
Debt-to-Equity 58.98
Debt-to-EBITDA -9.28
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -1.47
Distress
Grey
Safe
Beneish M-Score -1.89
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 49.32
9-Day RSI 58.45
14-Day RSI 60.25
6-1 Month Momentum % 0.84
12-1 Month Momentum % 92.8

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.82
Quick Ratio 1.38
Cash Ratio 0.76
Days Inventory 396.33
Days Sales Outstanding 79.09
Days Payable 117.92

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -71.1
Shareholder Yield % -20.68

Financials (Next Earnings Date:2024-03-08 Est.)

XERS's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:XERS

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Xeris Biopharma Holdings Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 152.668
EPS (TTM) ($) -0.45
Beta 0.71
Volatility % 54.98
14-Day RSI 60.25
14-Day ATR ($) 0.169657
20-Day SMA ($) 2.7435
12-1 Month Momentum % 92.8
52-Week Range ($) 1.13 - 3.26
Shares Outstanding (Mil) 138.12

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Xeris Biopharma Holdings Inc Filings

Filing Date Document Date Form
No Filing Data

Xeris Biopharma Holdings Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Xeris Biopharma Holdings Inc Frequently Asked Questions

What is Xeris Biopharma Holdings Inc(XERS)'s stock price today?
The current price of XERS is $3.04. The 52 week high of XERS is $3.26 and 52 week low is $1.13.
When is next earnings date of Xeris Biopharma Holdings Inc(XERS)?
The next earnings date of Xeris Biopharma Holdings Inc(XERS) is 2024-03-08 Est..
Does Xeris Biopharma Holdings Inc(XERS) pay dividends? If so, how much?
Xeris Biopharma Holdings Inc(XERS) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1